Arrayit Diagnostics Focused on Early Stage Disease Detection

SUNNYVALE, CA, Nov 12 (MARKET WIRE) --
Arrayit Corporation (OTCBB: ARYC) announced today that the company's
majority owned subsidiary, Arrayit Diagnostics, Inc., will launch the
most intensive marketing campaign in the company's thirteen-year history.
The company is currently developing several diagnostic tests that will
provide early detection for cancers, neurodegenerative diseases and other
disease states. By conclusively identifying the genomic and proteomic
biomarkers for specific diseases, these tests will enable early stage
diagnosis, leading to life saving and cost saving treatments. Arrayit
Diagnostics will promote the commercialization of these tests from its
international headquarters in Houston, Texas.

Arrayit Diagnostics has named John Howell as its CEO and President.
"Arrayit Diagnostics has the potential to globally renovate the health
care sector, allowing the diagnostics community to rethink the way
diseases are diagnosed and treated. Rather than reacting after symptoms
have already appeared, our tests will allow early detection, enabling
earlier intervention and treatment for patients, reducing costs compared
to later stage treatments, and potentially saving lives," stated John
Howell, who brings his extensive experience serving as a senior executive
of public corporations to the company.

"We are very pleased to launch Arrayit Diagnostics. It is an endeavor we
have been striving to achieve for some time. Arrayit Diagnostics will
utilize the strong foundation built by Arrayit Corporation, and we have
the utmost confidence in Mr. Howell to see that Arrayit Diagnostics
succeeds," stated Rene Schena, CEO of Arrayit Corp.

Utilizing a talented sales team and its massive network of 41
international life science and diagnostics distributors located in 38
countries, Arrayit will use this opportunity to expand its worldwide
customer base of 10,000 research labs to become a significant global
diagnostics company.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and
empowers the genetic, research, pharmaceutical, and diagnostic communities
through the discovery, development and manufacture of proprietary life
science technologies and consumables for disease prevention, treatment and
cure. It now offers over 650 products to a customer base of more than
10,000 laboratories worldwide, including most every major university,
pharmaceutical and biotech company, major agricultural and chemical
company, government agency, national research foundation and many private
sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in
this release that constitute forward-looking statements are based on
currently available information, involve certain risks and uncertainties
and the Company assumes no responsibility to update any such
forward-looking statement. The following factors, among others, may cause
actual results to differ materially from the results suggested in the
forward-looking statements. Risks that may result from changes in the
Company's business operations; our ability to keep pace with
technological advances; significant competition in the biomedical
business; our relationships with key suppliers and customers; quality and
consumer acceptance of newly introduced products; market volatility;
non-availability of product; excess inventory; price and product
competition; new product introductions, the outcome of our legal
disputes; the possibility that the review of our prior filings by the SEC
may result in changes to our financial statements; and the possibility
that stockholders or regulatory authorities may initiate proceedings
against Arrayit and/or our officers and directors as a result of any
restatements. Risk factors associated with our business, including some
of the facts set forth herein, are detailed in the Company's Form 10-K/A
for the fiscal year ended December 31, 2008 and Form 10-Q/A for the
fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal
second quarter ended June 30, 2009 and Form 10-Q/A for the fiscal third
quarter ended September 30, 2009.

Investor Contact:
Arrayit Corporation
Tel: 281-600-5000
investorinfo@arrayit.com
www.arrayit.com

Copyright 2009, Market Wire, All rights reserved.

-0-